Schinazi R F, Gosselin G, Faraj A, Korba B E, Liotta D C, Chu C K, Mathé C, Imbach J L, Sommadossi J P
Georgia VA Research Center for AIDS and HIV Infections, Veterans Affairs Medical Center, Decatur 30033.
Antimicrob Agents Chemother. 1994 Sep;38(9):2172-4. doi: 10.1128/AAC.38.9.2172.
(-)-beta-L-2',3'-Dideoxycytidine (beta-L-DDC), (+)-beta-D-2',3'-dideoxycytidine (beta-D-DDC), (-)-beta-L-2',3'-dideoxy-5-fluorocytidine (beta-L-FDDC), (-)-beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine (beta-L-FTC), and (+)-beta-D-1,3-dioxolane-5-fluorocytidine (beta-D-FDOC) were evaluated for their anti-hepatitis B virus (anti-HBV) activities in HBV-transfected human liver cells (2.2.15). The order of decreasing potency for the compounds at the 90% effect level was beta-D-FDOC > beta-L-FTC > beta-L-FDDC approximately beta-L-DDC >> beta-D-DDC. Inhibition of HBV in transfected liver cells by the cytosine nucleosides was selective. The beta-L-nucleoside-5'-triphosphates were consistently more potent inhibitors of woodchuck hepatitis virus DNA polymerase than the corresponding natural beta-D-enantiomers.
对(-)-β-L-2',3'-二脱氧胞苷(β-L-DDC)、(+)-β-D-2',3'-二脱氧胞苷(β-D-DDC)、(-)-β-L-2',3'-二脱氧-5-氟胞苷(β-L-FDDC)、(-)-β-L-2',3'-二脱氧-5-氟-3'-硫代胞苷(β-L-FTC)和(+)-β-D-1,3-二氧戊环-5-氟胞苷(β-D-FDOC)在乙肝病毒(HBV)转染的人肝细胞(2.2.15)中进行了抗乙肝病毒(抗HBV)活性评估。在90%效应水平下,这些化合物效力递减顺序为β-D-FDOC>β-L-FTC>β-L-FDDC≈β-L-DDC>>β-D-DDC。胞嘧啶核苷对转染肝细胞中HBV的抑制具有选择性。β-L-核苷-5'-三磷酸作为土拨鼠肝炎病毒DNA聚合酶抑制剂始终比相应的天然β-D-对映体更有效。